We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Kinnate Biopharma Inc
3 own
3 watching
Current Price
$3.73
$-0.12
(-3.12%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
165.4M
52-Week High
15.86
52-Week Low
2.32
Average Volume
0.22M
Dividend Yield
--
P/E Ratio
--
Market Capitalization165.4M52-Week High15.8652-Week Low2.32Average Volume0.22MDividend Yield--P/E Ratio--What does the Kinnate Biopharma Inc do?
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More
How much money does Kinnate Biopharma Inc make?
News & Events about Kinnate Biopharma Inc.
Ticker Report
26days ago
Kinnate Biopharma Inc. (NASDAQ:KNTE Get Rating) Director Carl L. Gordon purchased 350,749 shares of the businesss stock in a transaction on Friday, April 28th. The stock was acquired at an average price of $2.55 per share, with a total value of $894,409.95. Following the completion of...
Globe Newswire
1 year ago
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the ...
Zolmax
1 year ago
JPMorgan Chase & Co. increased its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE) by 60.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,147 shares of the companys stock after acquiring an additional 3,079 shares during the period. JPMorgan Chase...
Frequently Asked Questions
Frequently Asked Questions
What is Kinnate Biopharma Inc share price today?
Can Indians buy Kinnate Biopharma Inc shares?
How can I buy Kinnate Biopharma Inc shares from India?
Can Fractional shares of Kinnate Biopharma Inc be purchased?
What are the documents required to start investing in Kinnate Biopharma Inc stocks?
What is today’s traded volume of Kinnate Biopharma Inc?
What is today’s market capitalisation of Kinnate Biopharma Inc?
What is the 52-Week High and Low Range of Kinnate Biopharma Inc?
What percentage is Kinnate Biopharma Inc down from its 52-Week High?
What percentage is Kinnate Biopharma Inc up from its 52-Week Low?
Current Price
$3.73
$-0.12
(-3.12%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.